Financials
Financial year 2025
S.A. NOVO NORDISK PHARMA N.V. from Dilbeek, company number BE0414695586, closed financial year 2025 with a result of € 5.7 million after tax. For that financial year S.A. NOVO NORDISK PHARMA N.V. recorded revenue of € 197.1 million and equity of € 1.1 million. Compared with financial year 2024, the result moved from € 4.2 million to € 5.7 million. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
€ 1.1 million
▲ 9% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 5.7 million
▲ 36% vs 2024
Profit after tax over the fiscal year.
€ 5.6 million paid out
99 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
82.6
▼ 3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 14.9 million
▼ 4% vs 2024
€ 180,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 520,877
▲ € 519,216 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 50.1 million
▲ 162% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 98 days on average.
€ 4.4 million
▼ 16% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 128,846,171 | € 150,741,202 | € 150,928,178 | € 197,132,669 | ▲ 31% |
| Profit after taxes | € 3,126,551 | € 4,337,308 | € 4,175,438 | € 5,684,602 | ▲ 36% |
| Equity | € 874,455 | € 911,763 | € 987,200 | € 1,071,803 | ▲ 9% |
| Total debts | € 43,724,547 | € 53,457,457 | € 32,179,297 | € 66,095,202 | ▲ 105% |
| Cash | - | € 467 | € 0 | - | |
| Retained profit | € 805,455 | € 842,763 | € 918,200 | € 1,002,803 | ▲ 9% |
| Dividend | € 3,100,000 | € 4,300,000 | € 4,100,000 | € 5,600,000 | ▲ 37% |
| Balance sheet total | € 44,599,002 | € 54,369,220 | € 33,166,497 | € 67,167,005 | ▲ 103% |
| Employees (FTE) | 79.3 | 84.2 | 85.6 | 82.6 | ▼ 3 |
Key figures of S.A. NOVO NORDISK PHARMA N.V., fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to S.A. NOVO NORDISK PHARMA N.V.?
What happened at S.A. NOVO NORDISK PHARMA N.V. in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- David Marcus Svensson stepped down as director. NBB
- Jeppe Theisen stepped down as director. NBB
- Jonas Larsen stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 5.7 million (▲ 36% vs 2024). Source: NBB ↗
- David Marcus Svensson became a director. NBB
- Jeppe Theisen became a director. NBB
- Jonas Larsen became a director. NBB
- New establishment in Dilbeek. KBO
In short
From € 3.1 million profit in 2022 to € 5.7 million profit in 2025.
Paid € 7.4 million in corporate taxes since 2022.
Best year ever: 2025, with € 5.7 million profit.
Paid out € 17.1 million in dividends to the owners in total.
A new publication or filing at S.A. NOVO NORDISK PHARMA N.V.? We notify you, reason included.
Follow S.A. NOVO NORDISK PHARMA N.V.Databakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
David Marcus Svensson
Director
since 2026 · until 2032
Jeppe Theisen
Managing director
since 2026 · until 2032
Jonas Larsen
Director
since 2022 · until 2028
Establishments
Establishment units
Physical locations of this company
Alfons Gossetlaan 32E box 202
1702 Dilbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
MICROSOFT-CORP-MSN-AS-BLOCK - Microsoft Corporation, US
Website info
Features
Security
Details
- Company number
- 0414.695.586
- VAT number
- BE 0414.695.586
- Registered office
- Alfons Gossetlaan 32E bus 202, 1702 Dilbeek
- Names & denominations
- S.A. NOVO NORDISK PHARMA N.V.
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 20 September 1974
- Peppol
- Active · Active since 30 Mar 2026
- Contact
- novonordisk.be
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten